X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

    Continuous Bioprocessing Market to Surge by 2028

    Advancing Asia-Pacific Healthcare & Biopharma Innovation

    Generative AI in Pharma: Opportunities & Challenges

    Global Biopharma Market to Hit $566B by 2032

    AI Boosts Small Molecule Therapies for I&I Diseases

    Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

    Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

    Continuous Bioprocessing Market to Surge by 2028

    Advancing Asia-Pacific Healthcare & Biopharma Innovation

    Generative AI in Pharma: Opportunities & Challenges

    Global Biopharma Market to Hit $566B by 2032

    AI Boosts Small Molecule Therapies for I&I Diseases

    Celonic Group Signs Long-Term Multi-Year Manufacturing Service Agreement with LINDIS Biotech for the Commercial Supply of Catumaxomab

    Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Arena begins Phase Ib trial of APD334 to treat autoimmune diseases

Yuvraj_pawp by Yuvraj_pawp
5th June 2014
in Americas, Clinical Trials, News

US-based Arena Pharmaceuticals has started dosing patients in an investigational Phase Ib clinical trial of APD334, an oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor, to treat a number of autoimmune diseases.

The randomised, double-blind and placebo-controlled trial is designed to evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD334 in about 96 healthy adult volunteers.

Discovered by Arena, APD334 targets the S1P1 receptor, with therapeutic potential in a spectrum of autoimmune diseases, such as multiple sclerosis, psoriasis and rheumatoid arthritis.

S1P1 receptors have been shown to be involved in the modulation of several biological responses, including lymphocyte trafficking from lymph nodes to the peripheral blood.

“The company has optimised APD334 as a potent and selective small molecule S1P1 receptor agonist that reduces the severity of disease in preclinical autoimmune disease models.”

By isolating lymphocytes in lymph nodes, fewer immune cells are available in the circulating blood to effect tissue damage, the company said.

Arena senior vice-president and chief medical officer William Shanahan said: “We continue to make progress in advancing our novel pipeline of internally discovered drug candidates, and remain committed to our vision of leading the industry in the discovery, development and commercialisation of GPCR-directed medicines.”

Autoimmune diseases are characterised by an inappropriate immune response against substances and tissues that are normally present in the body.

A person’s antibodies and immune cells target healthy tissues, triggering an inflammatory response in an autoimmune reaction.

Reducing the immune or inflammatory response is a major goal in the treatment of autoimmune diseases.

The company is focused on improving health by seeking to bring new medicines targeting G protein-coupled receptors to patients.

Arena’s internally discovered drug, BELVIQ (lorcaserin HCl), is approved in the US, and the company is focused on discovering, developing and commercialising additional drugs to address unmet medical needs.

Tags: America
Previous Post

KIP THE HUMANS: DRUG DISCOVERY BY SIMULATING CELLS

Next Post

State-owned British research institute fund Clinical trial of Airsonett – an innovative Swedish asthma treatment

Related Posts

Americas

Thermo Fisher to acquire Solventum’s Purification & Filtration business for US$4.1bn

4th March 2025
Clinical Trials

Bio-Rad to Acquire Stilla Technologies by Q3 2025

28th February 2025
News

Types of Pharmaceutical Waste and How to Dispose of Them

31st December 2024
Developing Pharma Skills With Life Sci For Growth Initiative
News

UK Medicine Manufacturing Regulatory Framework For Care

6th November 2024
News

Nanoemulsion Drug Delivery Enhances Tuberculosis Care

6th November 2024
News

The Future of Drug Delivery Systems In Modern Medicine

6th November 2024
Next Post

Edge Therapeutics begins enrolment in second cohort of EG-1962 Phase I/II trial for aSAH

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In